9.73
+0.74(+8.23%)
Currency In USD
Address
395 Oyster Point Boulevard
Brisbane, CA 94080
United States of America
Phone
650 484 0899
Website
Sector
Healthcare
Industry
Biotechnology
Employees
181
First IPO Date
May 27, 2021
| Name | Title | Pay | Year Born |
| Dr. Jeremy Bender M.B.A., Ph.D. | Chief Executive Officer, President & Director | 1.2M | 1971 |
| Mr. Adam Dubow J.D. | General Counsel, Chief Compliance Officer & Secretary | 692,700 | 1967 |
| Mr. Charles N. York II, M.B.A. | Chief Operating Officer & Chief Financial Officer | 854,200 | 1977 |
| Ms. Lauren Merendino M.B.A. | Chief Commercial Officer | 0 | 1976 |
| Dr. Elly Barry M.D. | Chief Medical Officer | 0 | N/A |
| Ms. Jaa Roberson | Chief People Officer | 0 | N/A |
| Mr. John Stubenrauch Ph.D. | Chief Technology Officer | 0 | N/A |
| Dr. Davy Chiodin Ph.D., Pharm.D. | Chief Development Officer | 0 | N/A |
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.